Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be ...
U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures ...
MTAR may no longer be hidden for some, but its real test is durability. Operating quietly across India’s most demanding ...
GlycoEra AG, a biotechnology company pioneering best-in-class extracellular protein degraders, today announced the appointment of Petra Duda, M.D., Ph.D., as Chief Medical Officer. Dr. Duda brings ...
Understanding why cancer cells rely on specific genes is critical for designing effective targeted therapies. A new study ...
GUANGZHOU, GUANGDONG, CHINA, January 7, 2026 /EINPresswire.com/ -- The 138th China Import and Export Fair (Canton ...
Orca Bio announces $250M in aggregate financing to support launch readiness leading up to the Orca-T® PDUFA date of April 6, 2026.
AI prioritizes clinical trials by identifying unmet medical needs, optimizing resource allocation, and focusing on conditions ...
Our deep pipeline and cash runway into 2030 enable IDEAYA to advance key combinations and to address multiple indications ...
Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platformSidewinder's pipeline of precision bispecific ADCs combined with Lonza's clinically validated ...
Eavor’s Geretsried project marks the first time a closed-loop geothermal system has delivered electricity to a commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback